Almost half of patients who received the PARP inhibitor olaparib for newly diagnosed BRCA-mutated advanced ovarian cancer remained disease-free after 5 years, according to data presented by Susana Banerjee, MBBS, PhD, and colleagues during the ESMO Virtual Congress 2020 (Abstract 811MO). Patients treated with olaparib continued to benefit substantially beyond the end of treatment.
Susana Banerjee, MBBS, PhD
SOLO1
The phase III SOLO1 trial is the first to report long-term follow-up for patients with newly diagnosed advanced ovarian cancer.
The randomized trial tested if patients benefited from taking olaparib for 2 years of maintenance treatment following standard treatment in comparison to patients who were given placebo. After 5 years, 48.3% of patients treated with olaparib had not experienced disease progression and were still living with stable disease vs 20.5% of those taking placebo.
The results showed that the women treated with olaparib for 2 years following standard treatment had 56 months where the cancer didn’t progress, compared with 13.8 for individuals who received standard treatment only.
Dr. Banerjee, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and Reader at The Institute of Cancer Research, London, commented, “These results represent a significant step forward in the treatment of newly diagnosed advanced ovarian cancer and give us real hope for more long-term survivors. Previous research in PARP inhibitors in ovarian cancer has only been in patients with relapsed disease, so SOLO1 has given us the evidence to show that as a first-line therapy, it can have substantial benefit for patients earlier in the cancer pathway.”
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.
